Abstracts Archive - Page 16 of 2605 - ACR Meeting Abstracts

Abstract Number: 0011 • ACR Convergence 2025
KT502, a novel CD19-directed TCE (T-cell engager), leads to rapid and deep B-cell depletion with low cytokine release
Min Bao, John Wang, Jay Zhao and Weihao Xu, Kali Therapeutics, San Mateo, CA
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapies targeting CD19 have shown unprecedented effects in treatment-resistant autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 0049 • ACR Convergence 2025
Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
Jun Li, Katalin Mikecz and Adrienn Markovics, Rush University Medical Center, Chicago
Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative…
Abstract Number: 0105 • ACR Convergence 2025
Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
Guillaume LARID¹, Cassandre Dumonteix Moreau², Adrien JAMAI², Hanitriniaina Rabeony², Jean Claude LECRON², Elisabeth Gervais¹, Jean François JEGOU² and franck MOREL², ¹Poitiers University Hospital - Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France, ²Poitiers University - LITEC Laboratory UR ¹⁵⁵⁶⁰, Poitiers, France
Background/Purpose: Psoriatic disease is a systemic inflammatory condition which encompasses both cutaneous psoriasis (PsO), psoriatic arthritis (PsA) and multiple comorbidities. The chronic Imiquimod (IMQ) induced…
Abstract Number: 0005 • ACR Convergence 2025
LBL-047, A First-In-Class Anti-BDCA2/TACI Fusion Protein, Inhibits the Function of Both pDCs and B cells
Fengxia Li¹, Jianming Sun¹, Hailin Wang¹, Yan Zhu¹, Xiaoxiao Liu¹, Jing Li¹, Yurong Qin¹, Guojin Wu¹, Jing Guan¹, Min Chen¹, Jordan Zhu², Xiaoqiang Kang¹, Xiao Huang¹ and Hong Ling¹, ¹Nanjing Leads Biolabs Co., Ltd., Nan Jing, China (People's Republic), ²Nanjing Leads Biolabs Co., Ltd., Nan Jing
Background/Purpose: Blood dendritic cell antigen 2 (BDCA2) is specifically expressed on pDCs whose uncontrolled production of type I IFN play a crucial role in the…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 0020 • ACR Convergence 2025
Bulk RNA-sequencing of Leukocytoclastic Vasculitis Skin Biopsies Show Upregulation of Leukocyte Migration Genes
Anne Carlton, Lam Tsoi, Joseph Kirma, Jennifer Fox, Paul Harms and Johann Gudjonsson, University of Michigan, Ann Arbor, MI
Background/Purpose: Vasculitis encompasses multiple conditions united by end-organ damage due to an immune-mediated reaction against the vasculature. Leukocytoclastic vasculitis (LCV) is a subtype of cutaneous…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 0089 • ACR Convergence 2025
Expansion of PD-1hi Tfh and Tph cells in the peripheral blood of seropositive clinically suspect arthralgia patients: association with progression to rheumatoid arthritis
Maria-Eugenia Miranda-Carus¹, Mariana Gutierrez-Riart², Beatriz Nieto-Carvalhal³, Laura Nuño², Alejandro Villalba¹, Diana Peiteado¹, Irene Monjo Henry¹, Marta Novella-Navarro¹ and Eugenio de Miguel¹, ¹Hospital Universitario La Paz, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, ³Hospital Universitario La Paz, Mdrid
Background/Purpose: Subjects with clinically suspect arthralgia (CSA) are at risk for developing rheumatoid arthritis (RA) and therapeutic interventions may prevent or delay progression. Still, a…
Abstract Number: 0092 • ACR Convergence 2025
SynovAI: A Revolutionary AI Framework for Enhanced Detection and Differentiation of Rheumatoid Arthritis, Osteoarthritis, and Spondyloarthritis via Advanced Ultrasound Imaging
Mojtaba S. Fazli¹, Mariani Diaz Deluna², Suzanne Tamang² and Robert Fairchild², ¹Stanford University, San Francisco, CA, ²Stanford University, Stanford, CA
Background/Purpose: Rheumatology musculoskeletal ultrasound (MSKUS) is a powerful technique to identify and differentiate arthritidies joint pathology, yet MSKUS is highly dependent on user experience. Techniques…
Abstract Number: 0085 • ACR Convergence 2025
Single Cell RNA-seq Revealed Immune/epithelial Cell Abnormalities Underlying the Pathogenesis of Rheumatoid Arthritis-related Interstitial Lung Disease
Kensuke Suga¹, Amara Seng², Changfu Yao³, Tanyalak Parimon³, Youn Jung Choi², Justyna Fert-Bober⁴, Barry Stripp³, Jon Giles⁵, Peter Chen³ and Nunzio Bottini⁶, ¹Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Beverly Hills, CA, ²Kao Autoimmunity Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ³Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Cedars Sinai Medical Center, Beverly Hills, CA
Background/Purpose: Interstitial lung disease (ILD) is one of the extra-articular manifestations of rheumatoid arthritis (RA) characterized by inflammation and/or fibrosis. Clinically relevant RA-ILD occurs in…
Abstract Number: 0074 • ACR Convergence 2025
Rheumatoid Factors (RFs) in RA Patient Sera Do Not Bind To Fc-Free Certolizumab Pegol, But Do Bind To Fc-Containing Anti-TNF-α Biological DMARDs, Driving Immune Complex Formation and Cellular Clearance
Sophie Hopkin¹, Kathryn Malpas¹, David Kallenberg¹, Jacqueline O'Neill¹, Geofrey Odede¹, Kerry Tyson¹, Sue Cross¹, Tatiana SOKOLOVA², Bernard Lauwerys³, Baran Ufuktepe⁴, Patrick Durez⁵, Susanna Bidgood¹ and David Humphreys¹, ¹UCB Pharma, Slough, England, United Kingdom, ²Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, ³Systemic and Inflammatory Rheumatic Diseases Section, Institute of Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, ⁴UCB Pharma Istanbul, Turkey, istanbul, Turkey, ⁵Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium
Background/Purpose: RFs are polyclonal autoantibodies which bind the Fc domain of IgGs. Patients with RA and high RF levels experience reduced serum drug concentrations and…
Abstract Number: 0232 • ACR Convergence 2025
Hydroxychloroquine Blood Testing in Lupus: The Michigan Medicine Experience
Zeinab Saleh¹, Michelle Kahlenberg², Wendy Marder¹ and Emily Somers¹, ¹University of Michigan, Ann Arbor, MI, ²Michigan Medicine, Ann Arbor, MI
Background/Purpose: Measuring hydroxychloroquine (HCQ) blood levels in patients with systemic lupus erythematosus (SLE) can assess medication adherence and determine whether concentrations fall within the therapeutic…
Abstract Number: 0243 • ACR Convergence 2025
Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain
Carmen Lasa Teja¹, Laura Muñoz-Llopis², Diana Prieto-Peña³, Isla Morante Bolado⁴, José Luis Martín-Varillas⁵, Nerea Paz-Gandiaga⁶ and Ricardo Blanco⁷, ¹Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Riotuerto, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander , Spain, Santander, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain., Santander, Spain, ⁴Rheumatology, Hospital General Sierrallana, Torrelavega, Spain., Santander, ⁵Rheumatology Division, Hospital de Laredo. IDIVAL, Immunopathology Group. Santander, Spain., Laredo, Spain, ⁶Rheumatology, Hospital Comarcal de Laredo, Laredo, Spain., Santander, ⁷Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain
Background/Purpose: Systemic autoinflammatory diseases (SAIDs) are rare disorders characterized by recurrent episodes of fever, serositis, gastrointestinal symptoms, arthritis, and/or skin lesions. In adult-onset SAIDs, clinical…
Abstract Number: 0030 • ACR Convergence 2025
Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study
John Davis¹, Elizabeth Atkinson¹, Vanessa Kronzer¹, Cynthia Crowson², Afsaneh Alavi³, John Damianos¹, Loftus Edward¹, Joseph Murray¹, Ann Moyer¹ and Filippo Pinto e Vairo¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Stewartvillle, MN, ³Department of Dermatology, Mayo Clinic, Rochester, MN
Background/Purpose: The nucleotide-binding oligomerization domain-containing protein 2 (NOD2) gene is associated with risk for several inflammatory diseases, including Crohn disease, Blau syndrome, and Yao syndrome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].